TY - JOUR
T1 - In-depth clinico-pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers
AU - DeJesus-Hernandez, Mariely
AU - Finch, Ni Cole A.
AU - Wang, Xue
AU - Gendron, Tania F.
AU - Bieniek, Kevin F.
AU - Heckman, Michael G.
AU - Vasilevich, Aliaksei
AU - Murray, Melissa E.
AU - Rousseau, Linda
AU - Weesner, Rachael
AU - Lucido, Anthony
AU - Parsons, Meeia
AU - Chew, Jeannie
AU - Josephs, Keith A.
AU - Parisi, Joseph E.
AU - Knopman, David S.
AU - Petersen, Ronald C.
AU - Boeve, Bradley F.
AU - Graff-Radford, Neill R.
AU - de Boer, Jan
AU - Asmann, Yan W.
AU - Petrucelli, Leonard
AU - Boylan, Kevin B.
AU - Dickson, Dennis W.
AU - van Blitterswijk, Marka
AU - Rademakers, Rosa
N1 - Funding Information:
The research leading to these results has received funding by the National Institutes of Health (NIH) Grants R21 NS093118, R01 NS080882, R35 NS097261, R35 NS097273, P50 AG016574, P01 NS084974, and the ALS Therapy Alliance. Dr. Van Blitterswijk is a former recipient of the Milton Safenowitz Post Doctoral Fellowship for ALS Research from the ALS Association and is currently supported by the Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Clinical Research Fellowship. CReATe (U54 NS092091) is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS). CReATe is funded through collaboration between NCATS and the National Institute of Neurological Disorders and Stroke (NINDS).
Publisher Copyright:
© 2017, The Author(s).
PY - 2017/8/1
Y1 - 2017/8/1
N2 - A growing body of evidence suggests that a loss of chromosome 9 open reading frame 72 (C9ORF72) expression, formation of dipeptide-repeat proteins, and generation of RNA foci contribute to disease pathogenesis in amyotrophic lateral sclerosis and frontotemporal dementia. Although the levels of C9ORF72 transcripts and dipeptide-repeat proteins have already been examined thoroughly, much remains unknown about the role of RNA foci in C9ORF72-linked diseases. As such, we performed a comprehensive RNA foci study in an extensive pathological cohort of C9ORF72 expansion carriers (n = 63). We evaluated two brain regions using a newly developed computer-automated pipeline allowing recognition of cell nuclei and RNA foci (sense and antisense) supplemented by manual counting. In the frontal cortex, the percentage of cells with sense or antisense RNA foci was 26 or 12%, respectively. In the cerebellum, 23% of granule cells contained sense RNA foci and 1% antisense RNA foci. Interestingly, the highest percentage of cells with RNA foci was observed in cerebellar Purkinje cells (~70%). In general, more cells contained sense RNA foci than antisense RNA foci; however, when antisense RNA foci were present, they were usually more abundant. We also observed that an increase in the percentage of cells with antisense RNA foci was associated with a delayed age at onset in the frontal cortex (r = 0.43, p = 0.003), whereas no other associations with clinico-pathological features were seen. Importantly, our large-scale study is the first to provide conclusive evidence that RNA foci are not the determining factor of the clinico-pathological variability observed in C9ORF72 expansion carriers and it emphasizes that the distribution of RNA foci does not follow the pattern of neurodegeneration, stressing the complex interplay between different aspects of C9ORF72-related diseases.
AB - A growing body of evidence suggests that a loss of chromosome 9 open reading frame 72 (C9ORF72) expression, formation of dipeptide-repeat proteins, and generation of RNA foci contribute to disease pathogenesis in amyotrophic lateral sclerosis and frontotemporal dementia. Although the levels of C9ORF72 transcripts and dipeptide-repeat proteins have already been examined thoroughly, much remains unknown about the role of RNA foci in C9ORF72-linked diseases. As such, we performed a comprehensive RNA foci study in an extensive pathological cohort of C9ORF72 expansion carriers (n = 63). We evaluated two brain regions using a newly developed computer-automated pipeline allowing recognition of cell nuclei and RNA foci (sense and antisense) supplemented by manual counting. In the frontal cortex, the percentage of cells with sense or antisense RNA foci was 26 or 12%, respectively. In the cerebellum, 23% of granule cells contained sense RNA foci and 1% antisense RNA foci. Interestingly, the highest percentage of cells with RNA foci was observed in cerebellar Purkinje cells (~70%). In general, more cells contained sense RNA foci than antisense RNA foci; however, when antisense RNA foci were present, they were usually more abundant. We also observed that an increase in the percentage of cells with antisense RNA foci was associated with a delayed age at onset in the frontal cortex (r = 0.43, p = 0.003), whereas no other associations with clinico-pathological features were seen. Importantly, our large-scale study is the first to provide conclusive evidence that RNA foci are not the determining factor of the clinico-pathological variability observed in C9ORF72 expansion carriers and it emphasizes that the distribution of RNA foci does not follow the pattern of neurodegeneration, stressing the complex interplay between different aspects of C9ORF72-related diseases.
KW - Amyotrophic lateral sclerosis
KW - C9ORF72
KW - Frontotemporal dementia
KW - Frontotemporal lobar degeneration
KW - Motor neuron disease
KW - RNA foci
UR - http://www.scopus.com/inward/record.url?scp=85019203332&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019203332&partnerID=8YFLogxK
U2 - 10.1007/s00401-017-1725-7
DO - 10.1007/s00401-017-1725-7
M3 - Article
C2 - 28508101
AN - SCOPUS:85019203332
SN - 0001-6322
VL - 134
SP - 255
EP - 269
JO - Acta neuropathologica
JF - Acta neuropathologica
IS - 2
ER -